title: No Significant Reduction of Circulating Endothelial-Derived and Platelet-Derived Microparticles in Patients with Psoriasis Successfully Treated with Anti-IL12/23.
abstract: Psoriasis is associated with atherosclerosis, in which circulating microparticles play an important role. In severe psoriasis, there was an increase of endothelial- and platelet- microparticles which could be decreased by anti-TNFα. However, whether anti-IL-12/23 treatment would decrease the level of microparticles remains unknown. Our study showed that, despite the clinical improvement of psoriasis after IL-12/13 blockage, the increased levels of circulating CD41a and CD31 microparticles were unchanged after anti-IL-12/23. This result suggested that anti-IL12/23 treatment may not alter the development of cardiovascular disease in patients with psoriasis.
authors.affiliation: Department of Dermatology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Ta-Pei Road 123, Niao-Sung, Kaohsiung 83301, Taiwan.
authors.forename: Ji-Chen
authors.initials: JC
authors.lastname: Ho
authors.affiliation: Department of Dermatology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Ta-Pei Road 123, Niao-Sung, Kaohsiung 83301, Taiwan.
authors.forename: Chih-Hung
authors.initials: CH
authors.lastname: Lee
authors.affiliation: Department of Dermatology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Ta-Pei Road 123, Niao-Sung, Kaohsiung 83301, Taiwan.
authors.forename: Shang-Hung
authors.initials: SH
authors.lastname: Lin
mesh_terms: D000328:Adult; D000368:Aged; D001792:Blood Platelets / Q000187:drug effects / Q000276:immunology / Q000473:pathology*; D055252:Cell-Derived Microparticles / Q000187:drug effects / Q000276:immunology / Q000473:pathology*; D066026:Endothelial Progenitor Cells / Q000187:drug effects / Q000276:immunology / Q000473:pathology*; D005260:Female; D006801:Humans; D053762:Interleukin-12 Subunit p40 / Q000276:immunology; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000097:blood* / Q000276:immunology / Q000628:therapy*; D016896:Treatment Outcome; D000069549:Ustekinumab / Q000008:administration & dosage* / Q000276:immunology
chemical_list: D053762:Interleukin-12 Subunit p40; D000069549:Ustekinumab